<i>In vivo</i> isolation of circulating tumor cells in patients with different stages of prostate cancer

Theil, Gerit; Boehm, Catrin; Fischer, Kersten; Białek, Joanna; Hoda, Raschid; Weber, Ekkehard; Schönburg, Sandra; Kawan, Felix; Fornara, Paolo

doi:10.3892/ol.2021.12618

Cited by 17 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, the CC-PCa and CC-EpCAM have lower specificity but higher sensitivity of CTC capturing compared to the Ficoll * system. Furthermore, in our previous trial, the EpCAM wire demonstrated in vivo a similar diagnostic accuracy to the FDA-approved CellSearch System [ 28 ] which confirmed in vivo application of the CellCollector. Unexpectedly, CTC cultivation was successful only with the Ficoll * system.…”

Section: Discussionsupporting

confidence: 55%

“…The aim of our preliminary investigation was to evaluate and develop a PCa-specific CTC isolation method. For this purpose, we used the CellCollector (CC-EpCAM), a medical wire that enables in vivo CTC isolation with a monoclonal antibody directed to the cell-surface-expressed EpCAM of CTCs in the peripheral blood [ 28 , 29 , 30 , 31 ]. In our trial, we functionalized the new form of the CellCollector with EpCAM antibody or with previously mentioned PCa markers (CC-PCa).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer (PCa)-specific CTC identification and analysis is crucial. We used the CellCollector EpCAM-functionalized system (CC-EpCAM) and evaluated and developed a PCa-functionalized version (CC-PCa); we then compared CTC isolation techniques that exploit the physical and biological properties of CTCs. We established two cohorts of metastatic PCa patients (mPCa; 15 in cohort 1 and 10 in cohort 2). CTC cultivation experiments were conducted with two capturing methods (Ficoll and ScreenCell). The most sensitive detection rates and highest CTC counts were reached with the CC-PCa and ScreenCell system. Patients with ≥5 CTCs isolated with CC-EpCAM had an overall survival (OS) of 0.93 years, and patients with ≥5 CTCs isolated with CC-PCa had an OS of 1.5 years in cohort 1. Nevertheless, we observed the highest sensitivity and specificity for 24-month survival by the Ficoll with CD45 depletion and ScreenCell system with May-Grunwald Giemsa (MGG) staining. The EpCAM molecule is an essential factor related to OS for CTC isolation based on biological properties in mPCa patients. The best-suited CTC capture system is not limited to one characteristic of cells but adapted to downstream analysis.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Introductionmentioning

confidence: 99%

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, if the stemness phenotype is responsible for metastasis, it is probably that neither EpCAM nor E-cadherin would be expressed on the CSCs [ 50 , 51 ]. When we were comparing normal men, localized PCa and metastatic patients, a higher number of CTCs-EpCAM+ was found in the last group [ 52 ]. On the other hand, in a transgenic mice model, only the cells undergoing EMT were capable of self-renewal compared with their epithelial and mesenchymal counterparts [ 4 , 53 ].…”

Section: Cancer Stem Cells and Epithelial–mesenchymal Transition Cont...mentioning

confidence: 99%

Cancer Stemness/Epithelial–Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target

Castellón

Indo

Contreras

2022

IJMS

View full text Add to dashboard Cite

Prostate cancer (PCa) is a leading cause of cancer death in men, worldwide. Mortality is highly related to metastasis and hormone resistance, but the molecular underlying mechanisms are poorly understood. We have studied the presence and role of cancer stem cells (CSCs) and the Epithelial–Mesenchymal transition (EMT) in PCa, using both in vitro and in vivo models, thereby providing evidence that the stemness–mesenchymal axis seems to be a critical process related to relapse, metastasis and resistance. These are complex and related processes that involve a cooperative action of different cancer cell subpopulations, in which CSCs and mesenchymal cancer cells (MCCs) would be responsible for invading, colonizing pre-metastatic niches, initiating metastasis and an evading treatments response. Manipulating the stemness–EMT axis genes on the androgen receptor (AR) may shed some light on the effect of this axis on metastasis and castration resistance in PCa. It is suggested that the EMT gene SNAI2/Slug up regulates the stemness gene Sox2, and vice versa, inducing AR expression, promoting metastasis and castration resistance. This approach will provide new sight about the role of the stemness–mesenchymal axis in the metastasis and resistance mechanisms in PCa and their potential control, contributing to develop new therapeutic strategies for patients with metastatic and castration-resistant PCa.

show abstract

“…Another promising in vivo method for CTC capture, the GILUPI CellCollector ® , facilitates the screening of large volumes of blood using a medical wire coated with antibodies against EpCAM that is placed intravenously to capture CTCs that flow by [ 38 ]. Several studies have found CellCollector ® detects a larger number of CTCs than the CellSearch system; however, this technology has not yet been analysed for use in haematological malignancies [ 39 , 40 ]. Studies focusing on the proteomic analysis of the intracellular proteome of CTC cells are limited.…”

Section: Bloodmentioning

confidence: 99%

Clinical Proteomics of Biofluids in Haematological Malignancies

Dunphy

O’Mahoney

Dowling

et al. 2021

IJMS

View full text Add to dashboard Cite

Since the emergence of high-throughput proteomic techniques and advances in clinical technologies, there has been a steady rise in the number of cancer-associated diagnostic, prognostic, and predictive biomarkers being identified and translated into clinical use. The characterisation of biofluids has become a core objective for many proteomic researchers in order to detect disease-associated protein biomarkers in a minimally invasive manner. The proteomes of biofluids, including serum, saliva, cerebrospinal fluid, and urine, are highly dynamic with protein abundance fluctuating depending on the physiological and/or pathophysiological context. Improvements in mass-spectrometric technologies have facilitated the in-depth characterisation of biofluid proteomes which are now considered hosts of a wide array of clinically relevant biomarkers. Promising efforts are being made in the field of biomarker diagnostics for haematologic malignancies. Several serum and urine-based biomarkers such as free light chains, β-microglobulin, and lactate dehydrogenase are quantified as part of the clinical assessment of haematological malignancies. However, novel, minimally invasive proteomic markers are required to aid diagnosis and prognosis and to monitor therapeutic response and minimal residual disease. This review focuses on biofluids as a promising source of proteomic biomarkers in haematologic malignancies and a key component of future diagnostic, prognostic, and disease-monitoring applications.

show abstract

In vivo isolation of circulating tumor cells in patients with different stages of prostate cancer

Cited by 17 publications

References 30 publications

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer

Cancer Stemness/Epithelial–Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target

Clinical Proteomics of Biofluids in Haematological Malignancies

Contact Info

Product

Resources

About